openPR Logo
Press release

Pulmonary Arterial Hypertension Market Share, Trends, Size, Major Players And Forecast To 2033

02-27-2024 06:26 AM CET | Health & Medicine

Press release from: The Business research company

Pulmonary Arterial Hypertension Market Analysis

Pulmonary Arterial Hypertension Market Analysis

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Pulmonary Arterial Hypertension Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $7.85 billion in 2023 to $8.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (pah), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11.99 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of pah drugs and therapies, integration of precision medicine in pah treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

Market Segmentation:
The pulmonary arterial hypertension market covered in this report is segmented -
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, Online

Major Driver - Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth
The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500-1000 new cases each year, and Europe is expected to have similar incidence rates.

Competitive Landscape:
Major companies operating in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Top Trend - Innovative Technological Breakthroughs Transforming Pulmonary Arterial Hypertension Treatment Landscape
Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drug sector are focusing on developing new medicines to improve and cure these diseases. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients enhance their exercise abilities, reduce breathing difficulties, have a low tolerance for exertion, and have a higher mortality rate.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Pulmonary Arterial Hypertension Market Characteristics
3. Pulmonary Arterial Hypertension Market Trends And Strategies
4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario
5. Pulmonary Arterial Hypertension Market Size And Growth
…..
27. Pulmonary Arterial Hypertension Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Arterial Hypertension Market Share, Trends, Size, Major Players And Forecast To 2033 here

News-ID: 3400415 • Views:

More Releases from The Business research company

Increasing Financial Fraud Incidents Propel Accounting and Auditing Market: A Key Catalyst Accelerating Accounting And Auditing Market Growth in 2025
Increasing Financial Fraud Incidents Propel Accounting and Auditing Market: A Ke …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Accounting And Auditing Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for accounting and auditing has seen a robust growth in the past few years. It is expected to increase from $222.35 billion in 2024 to $238.28 billion in 2025, reflecting a
Supply Chain Finance Market Expected to Achieve 8.6% CAGR by 2029: Growth Forecast Insights
Supply Chain Finance Market Expected to Achieve 8.6% CAGR by 2029: Growth Foreca …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Supply Chain Finance Market Size By 2025? The market size for supply chain finance has been experiencing a robust expansion in the past few years. The market, which is projected to escalate from $12.47 billion in 2024 to $13.42 billion in 2025, is expected to
Personal Loans Market on Track for Strong Growth, Estimated to Grow at 10.7% CAGR Through 2029
Personal Loans Market on Track for Strong Growth, Estimated to Grow at 10.7% CAG …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Personal Loans Market Through 2025? The personal loans industry has seen robust growth in recent years. The market size is projected to increase from $778.34 billion in 2024 to $854.94 billion in 2025, with a compound annual growth rate (CAGR) of 9.8%.
Key Trends Reshaping the Mobile Wallet Market: Revolut Launches Innovative Mobile Wallet Feature to Enhance International Money Transfers Industry Transformation
Key Trends Reshaping the Mobile Wallet Market: Revolut Launches Innovative Mobil …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Mobile Wallet Market Size Growth Forecast: What to Expect by 2025? The scale of the mobile wallet market has experienced a monumental expansion in the past few years. Its morphology will evolve from $2109.19 billion in 2024 to a staggering $2754.87 billion by 2025, reflecting a compound annual growth

All 5 Releases


More Releases for Pulmonary

Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028. The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
03-15-2017 | Health & Medicine
TMR
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments